Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma

European Journal of Haematology

Volumn 93, Issue 2, 2014, Pages 172-174

  Vangsted, Annette J ^a,b   Klausen, Tobias W ^c   Gimsing, Peter ^b   Abildgaard, Niels ^d   Andersen, Niels F ^e   Gang, Anne O ^a   Holmström, Morten ^a   Gregersen, Henrik ^f   Vogel, Ulla ^g   Schwarz, Peter ^h   Jørgensen, Niklas R ^h  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f AALBORG UNIVERSITY HOSPITAL   (Denmark)

^g NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^h GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DISEASE; CYTOKINE RELEASE; GENE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LETTER; MULTIPLE MYELOMA; OVERALL SURVIVAL; P2RX7 GENE; PRIORITY JOURNAL; SPINE FRACTURE; TUMOR GENE; ALLELE; FEMALE; GENE FREQUENCY; GENETICS; GENOTYPING TECHNIQUE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL;

P2RX7 PROTEIN, HUMAN; P2RY2 PROTEIN, HUMAN; PURINERGIC P2X7 RECEPTOR; PURINERGIC P2Y2 RECEPTOR;

ALLELES; FEMALE; GENE FREQUENCY; GENOTYPING TECHNIQUES; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; RECEPTORS, PURINERGIC P2X7; RECEPTORS, PURINERGIC P2Y2; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84904347708     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12353     Document Type: Letter

References (8)

1. Grol MW, Panupinthu N, Korcok J, Sims SM, Dixon SJ. Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal 2009;5:205-21.
2. Farrell AW, Gadeock S, Pupovac A, Wang B, Jalilian I, Ranson M, Sluyter R. P2X7 receptor activation induces cell death and CD23 shedding in human RPMI 8226 multiple myeloma cells. Biochim Biophys Acta 2010;1800:1173-82.
3. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P, Hokland P, Lillevang ST, Vogel U. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007;120:1036-45.
4. Wesselius A, Bours MJ, Agrawal A, Gartland A, Dagnelie PC, Schwarz P, Jorgensen NR. Role of purinergic receptor polymorphisms in human bone. Front Biosci (Landmark Ed) 2011;16:2572-85.
5. Jorgensen NR, Husted LB, Skarratt KK, et al. Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet 2012;20:675-81.
6. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998;316:1236-8.
7. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, Wiley JS. Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 2010;24:2916-27.
8. Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 1999;31:207-19.